Biblio
Theranostics in Hematooncology. J Nucl Med. 2023.
. Quantification of letermovir in human serum using high-performance liquid chromatography with diode array detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1159:122399.
. A day 14 endpoint for acute GVHD clinical trials. Transplant Cell Ther. 2024.
CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. Nuklearmedizin. 2024.
C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety Profile. Clin Nucl Med. 2023.
. CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis. Front Immunol. 2023;14:1148841.